An overview of the aims and initiatives of the nAMD Barometer Programme
Age-related macular degeneration (AMD) is the third largest cause of vision loss. Over 8 million people have vision loss due to AMD. Of these, 1.9 million are blind and 6.2 million experience moderate to severe vision impairment.
For every person that experiences vision impairment and blindness from AMD, there are many more living with early stage AMD who need comprehensive and integrated people centred eye care services to prevent vision loss (Adelson et al. 2020).
To overcome these barriers, a coalition of international experts in retinal disease, vision care and ageing has come together to optimise clinical practice for the treatment of neovascular age-related macular degeneration (nAMD).
By considering the needs and perspectives of patients, caregivers, and healthcare professionals, we can enhance care, improve treatment outcomes and minimise impact of nAMD.
The nAMD Barometer Leadership Coalition
The nAMD Barometer Leadership Coalition is an international group of experts in the field of retinal disease, vision and diabetes care, and ageing. It was established in 2018 to develop evidence-based solutions for the optimal management of nAMD.
The Leadership Coalition aims to overcome barriers facing patient adherence to and persistence with recommended anti-VEGF treatment by developing evidence-based interventions to optimise care and ultimately improve long-term patient outcomes.
The Barometer Programme is managed by clinical leaders in ophthalmology as well as representatives from the International Federation on Ageing (IFA), International Agency for Prevention of Blindness (IAPB), International Diabetes Federation (IDF) and Bayer. The activities of the Barometer Programme are funded and facilitated by Bayer where the scientists, and representatives from IFA, IAPB and IDF, retain decision authority to the scope, methods, analysis of findings and dissemination of the outputs of the Barometer Programme.
Program initiatives and outcomes
The barriers preventing optimal nAMD treatment are multifactorial and complex. Understanding the key drivers of poor adherence and persistence from multiple perspectives is essential to support changes in behaviour that can help to optimise treatment outcomes.
In order to do this, the nAMD Barometer Leadership Coalition are conducting a series of initiatives designed to generate an evidence base that will be used to inform future interventions.
Click here to visit the resource zone, where you can access a variety of useful educational tools and materials to support your clinical practice and optimise patient care in nAMD, including podcasts, HCP interviews and recordings of the Barometer Ambassador Webinar Series!